Bio & Insurance Information

Dr. Agustin Garcia graduated from the Universidad Anahuac School of Medicine and completed his residency program at the University of Illinois College of Medicine. Then, he did a fellowship at the University of Southern California. He is specialized in Medical Oncology and board certified in Oncology. Dr. Garcia has been in practice for more 20 years and is affiliated with the USC Norris Cancer Hospital, Keck Hospital of USC, and the Ronald Reagan UCLA Medical Center. During his career, he has also contributed to several research publications.



Education & Training

Universidad Anahuac

Medical School

University of Illinois College of Medicine

Residency

University of Southern California - LAC+USC Medical Center

Fellowship

Board Certifications

American Board of Internal Medicine - Oncology

Medical License

LA State Medical License: 2015 - 2016

Hospitals & Clinics

Keck Hospital of USC - Medical Center

Languages: English/Spanish

(323) 442-8500

1500 San Pablo St

Los Angeles, California 90033

Read More

Ronald Reagan UCLA Medical Center

Languages: English/Spanish

(310) 825-9111

757 Westwood Plaza

Los Angeles, California 90095

Read More

USC Norris Comprehensive Cancer Center

Languages: English/Spanish

(323) 865-3000

1441 Eastlake Avenue

Los Angeles, California 90033

Read More

Publications

Dr. Agustin Garcia has contributed to 3 publications.

Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.

Lee, S. C.,Grant, E.,Sheth, P.,Garcia, A. A.,Desai, B.,Ji, L.,Groshen, S.,Hwang, D.,Yamashita, M.,Hovanessian-Larsen, L.; J Ultrasound Med. 1900 Jan 01.

See more >>

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Piatek, C. I.,Raja, G. L.,Ji, L.,Gitlitz, B. J.,Dorff, T. B.,Quinn, D. I.,Hu, J.,El-Khoueiry, A. B.,Pham, H. Q.,Roman, L.,Garcia, A. A.; Cancer Chemother. Pharmacol.. 2014 Nov 07.

See more >>

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada, A.,Garcia, A. A.,Chan, S.,Jerusalem, G. H.,Coleman, R. E.,Huizing, M. T.,Mehdi, A.,O'Reilly, S. M.,Hamm, J. T.,Barrett-Lee, P. J.,Cocquyt, V.,Sideras, K.,Young,...; Lancet Oncol.. 2013 Oct 08.

See more >>